Neurochemical abnormalities in chronic fatigue syndrome: a pilot magnetic resonance spectroscopy study at 7 Tesla.
Godlewska, Beata R, Williams, Stephen, Emir, Uzay E et al. · Psychopharmacology · 2022 · DOI
Quick Summary
Researchers used a powerful brain scanning technique to measure chemicals in the brains of people with ME/CFS and compared them to healthy people. They found that people with ME/CFS had lower levels of three important brain chemicals: glutathione (which helps protect against cell damage), creatine (which helps produce energy), and myo-inositol (which is important for brain cell function). These findings suggest that ME/CFS may involve problems with energy production and cell damage in the brain.
Why It Matters
These findings provide objective biological evidence of neurochemical abnormalities in ME/CFS, moving beyond symptom description toward understanding underlying brain dysfunction. If validated, these biomarkers could aid diagnosis and potentially identify targets for treatment, such as antioxidant or mitochondrial-supporting interventions.
Observed Findings
Significantly reduced glutathione levels in anterior cingulate cortex of CFS patients versus controls
Significantly reduced total creatine levels in CFS patients versus controls
Significantly reduced myo-inositol levels in CFS patients versus controls (remained significant with alternative statistical referencing)
Small sample size: 22 CFS patients and 13 healthy controls
Single brain region examined (anterior cingulate cortex)
Inferred Conclusions
Oxidative and energetic stress may play a role in CFS pathophysiology
Glial dysfunction in the brain may contribute to CFS
Nutritional or metabolic interventions targeting oxidative stress and energy production could potentially be therapeutic
Neurochemical abnormalities in CFS warrant further investigation as potential biomarkers
Remaining Questions
Are these neurochemical abnormalities specific to ME/CFS or present in other conditions?
Do these changes correlate with symptom severity or specific symptom clusters?
What This Study Does Not Prove
This small pilot study does not establish that these neurochemical changes cause ME/CFS symptoms or are unique to this condition. The cross-sectional design cannot determine whether the abnormalities precede illness onset or result from chronic illness. Results must be replicated in larger samples before being considered confirmed biological markers.